SuperSpectra
Noninvasive Imaging Device for Alzheimer's Disease
Company Overview
Snapshot
Founded in May 2020 by Yevgeny Beiderman and Zeev Zalevsky, SuperSpectra operates with 1–10 employees. The company ceased operations in September 2024.
Business overview
SuperSpectra develops a noninvasive imaging device designed for the early detection and monitoring of Alzheimer's disease. The core technology provides high-accuracy quantitative measurements of CSF A and tau biomarkers through real-time imaging. This approach offers a noninvasive, radiation-free, pain-free, and risk-free alternative to direct CSF analysis, allowing for frequent testing. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices, serving healthcare providers and patients.
Log in to access full profile ›Company Intelligence Q&A
- What is SuperSpectra's primary focus?
- SuperSpectra focuses on developing a noninvasive imaging device for the early detection and degradation follow-up of Alzheimer's disease.
- What technology does SuperSpectra utilize?
- SuperSpectra utilizes a noninvasive imaging device to measure CSF A and tau quantitative results, providing real-time imaging of Alzheimer's disease biomarkers.
- When was SuperSpectra founded?
- SuperSpectra was founded in May 2020.
- Who are the founders of SuperSpectra?
- The co-founders of SuperSpectra are Yevgeny Beiderman and Zeev Zalevsky.
- What is the current operational status of SuperSpectra?
- SuperSpectra ceased to operate in September 2024.